Baselga / Sole´ / Strasbourg Cedex / L. A. / Cardiff / Los Angeles / /
Company
Sigma Chemical Co. / Norton / Salomon / Jensen B. V. / Intergroup / Southwest Oncology Group / Zymed Inc. / C. B. A. E. / /
Country
France / United States / / /
Event
FDA Phase / / /
IndustryTerm
protein product / treatment of stage II breast cancer / treatment of breast cancer / statistical software / /
MedicalCondition
node-positive early breast cancer / node-negative early breast cancer / high-risk node-positive operable breast cancer / II breast cancer / carcinoma / metastatic disease / metastatic breast cancer / invasive tumor / breast tumor / only noninvasive tumor / breast cancer / each breast tumor / Median tumor / tumor / congestive heart failure / breast cancers / lymph node-positive breast cancer / adenocarcinomas / hormone receptor-negative breast cancer / Cancer / tumors / strongly positive carcinoma / J. Cancer / progressive disease / node-negative breast cancer / tumour / breast and ovarian cancer / breast tumors / node-negative breast carcinomas / W. L. Human breast cancer / stable disease / residual invasive tumor / acute myeloid leukemia / node-positive hormone receptor-positive tumors / primary tumor / /
Centre de Lutte Contre le Cancer / Department of Medical Oncology / /
Person
Ross / Gabrielle Taglang / Mansour / Clarck / Anne Escande / Gary M. Clark / Breast Cancer Depends / Diana Pursglove / Slamon / Pierre Haegele / Jean-Pierre Ghnassia / Ricardo Mors / Godolphin / / /
Position
D. J. / model / stepwise selection was used / R. N. / using Fisher / /
Vol. 7, 1577–1581, June[removed]Clinical Cancer Research 1577 Chemotherapy Response of Breast Cancer Depends on HER-2 Status and Anthracycline Dose Intensity in the